<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>sinovacexh99_2.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE 8.11.04
<TEXT>






EXHIBIT 99.2
------------


    SINOVAC BIOTECH UPDATES ON ITS APPLICATION TO THE AMERICAN STOCK EXCHANGE
    -------------------------------------------------------------------------
      (AMEX) AND ANNOUNCES THE APPOINTMENT OF NEW ADDITIONS TO THE BOARD OF
      ---------------------------------------------------------------------
                                    DIRECTORS
                                    ---------

BEIJING,  11 August,  2004 - Sinovac  Biotech Ltd.  ("Sinovac")  ("the Company")
(NASD OTC-BB:  SNVBF) updates on the  forthcoming  listing on the American Stock
Exchange (AMEX). Sinovac's application for listing on AMEX has progressed to the
point that  management  believes  the Company  will be listed in August or early
September of 2004.

Once accepted on the American Stock Exchange, Sinovac will again demonstrate its
leadership  as  one  of  China's  most  modern,  publicly  traded  biotechnology
companies.  Sinovac  management  believes  that the Company will derive  several
benefits  from its  listing on AMEX.  Once  listed,  Sinovac  will  become  more
desirable to institutional  investors,  receive broader investor awareness,  and
improved share price stability and liquidity.

In continuing efforts to ensure good corporate governance, Sinovac announces the
appointment  of Mr. Simon J. Anderson and Mr. Hao You to the Company's  Board of
Directors. In addition,  Sinovac has appointed a new audit committee,  comprised
of Dr. K.K.  Ong, Mr. Simon J.  Anderson and Mr. Hao You in order to ensure that
the audit  committee is  comprised  entirely of expert,  impartial  directors as
required by AMEX corporate governance standards.

Mr. Simon J. Anderson brings excellent  credentials to Sinovac. Mr. Anderson has
been a major partner and Vice  President of MCSI  Consulting  Services Inc. from
1996 to present.  Mr.  Anderson is both a Chartered  Accountant  and a Chartered
Business  Valuator  and from 1994 to 1996 was a partner  with BDO  Dunwoody,  an
international  accounting and consulting  firm, where he specialized in mergers,
acquisitions  and  valuations.  Mr.  Anderson  was  admitted  as a member of the
Institute of Chartered Accountants in British Columbia in 1986. He has also been
a member of the Canadian  Institute of Charter Business Valuators since 1990. In
addition,  Mr.  Anderson is a director  and/or Chief  Financial  Officer of four
other public companies.

Mr. Hao You has equally  impressive  credentials.  Mr. You is currently the Vice
President of SIMCOM international  Holdings,  Inc. ("SIMCOM").  He has extensive
knowledge of and is responsible for SIMCOM's  marketing and sales efforts in the
Asia Pacific region,  which includes  establishing  and  maintaining  successful
business  relations  with relevant  trade  organizations,  government  agencies,
technical societies and various other  organizations.  Sinovac believes that Mr.
You's business savvy and enthusiasm combined with his business relationships and
his  background  in  marketing,   engineering  and  management  will  contribute
tremendously to the successful growth of Sinovac.

Dr.  Wei  Dong  Yin,  president  of  Sinovac  commented,   "these   developments
demonstrate  how  we  continue  to  develop  our  business  with  diligence  and
efficiency,  as we strive to build a solid  foundation  for sales  growth of our
approved  vaccine products and for the advancement of the other vaccines that we
are currently developing."

ABOUT SINOVAC BIOTECH LTD.
--------------------------

Sinovac    Biotech   Ltd.    specializes    in   the   research,    development,
commercialization,  and sales of human vaccines for infectious illnesses such as
Hepatitis A and Hepatitis B, influenza and "SARS".

Sinovac is one of the leading emerging biotechnology companies in China. Working
closely with Chinese public health  officials,  Sinovac focuses on manufacturing
and marketing human-use vaccines and related products, and currently markets its
vaccine for  Hepatitis A. Sinovac is currently  the only company in the world to
have commenced human clinical trials for a vaccine to prevent SARS.

For further  information  please refer to the Company's  filings with the SEC at
www.sec.gov or refer to Sinovac's website at www.sinovac.com.

Contact: Sinovac Investor Relations at (888) 888 8312 or (604) 684-5990 or email
to info@sinovac.com
   ----------------



<PAGE>






THIS NEWS RELEASE MAY INCLUDE  FORWARD-LOOKING  STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES  SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED,  WITH
RESPECT  TO  ACHIEVING  CORPORATE  OBJECTIVES,   DEVELOPING  ADDITIONAL  PROJECT
INTERESTS,   SINOVAC'S   ANALYSIS  OF   OPPORTUNITIES  IN  THE  ACQUISITION  AND
DEVELOPMENT  OF VARIOUS  PROJECT  INTERESTS  AND CERTAIN  OTHER  MATTERS.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM  ACT  OF  1995  AND  INVOLVE  RISKS  AND
UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM THOSE
IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.




</TEXT>
</DOCUMENT>
